Certara, Inc. (CERT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Certara Inc. CFO John Gallagher, speaking at the Morgan Stanley Global Healthcare Conference, outlined the company's strategy to accelerate growth beyond its current mid-single-digit organic profile amidst a subdued market environment. He emphasized ongoing investments in R&D, building on prior successful expenditures in sales and marketing that have already yielded accelerated growth, particularly among Tier 3 customers. This strategic focus on internal investment aims to enhance Certara's growth trajectory despite broader market headwinds.

Analysis

Certara's management is publicly addressing its current mid-single-digit organic growth by implementing a strategic investment plan designed to accelerate performance despite what the CFO terms a 'subdued' end market. The company outlined a two-phase approach, highlighting that the initial phase of investment in sales and marketing has already successfully built out its commercial organization and is delivering tangible results, specifically citing accelerated growth with its Tier 3 customers. The next phase, which is currently underway and extends into the next year, involves increased investment in R&D. This signals a clear strategy to drive future growth through internal innovation and product development, positioning the company to potentially outperform the challenging market environment by enhancing its core offerings rather than relying on market tailwinds.

Key Decisions for Investors

• Investors should monitor upcoming quarterly results for concrete evidence that the current R&D investment phase is translating into accelerated top-line growth, similar to the positive impact reported from the prior sales and marketing spending.
• Given the subdued market backdrop, Certara's organic growth rate should be benchmarked against direct industry peers to assess whether its investment strategy is generating alpha and market share gains.
• The focus on internal investment suggests a long-term value creation story, so investors may consider the stock for a longer horizon, but should remain patient as the full financial impact of R&D spending may not be immediate.